20.4 C
Sunday, May 28, 2023
Home Cancer Immunotherapy

Cancer Immunotherapy

Here for the Socks: Building the Physician-Patient Relationship in an Unexpected Way

By Jon Steinmetz, DOA few months ago, at the start of my second year as a hematology oncology fellow, I attempted to take stock of the most valuable lessons I had learned in my first year. Among the pathology conferences, difficult family conversations, and many tedious smear reviews, one series of patient interactions struck...

Cancer Immunotherapy Drugs Driving End-of-Life Cost Increases

Immunotherapy drugs accounted for 84% of the overall increase in Medicare Part B spending for end-of-life outpatient cancer care. Medscape Medical News

Ultralow Dose of Nivolumab Offers Huge Cost Savings

A clinical trial from India raises the possibility of huge cost savings by using ultralow immunotherapy doses in the treatment of head and neck cancer. Medscape Medical News

New Standard of Care for Early dMMR/MSI-H Colorectal Cancer?

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care. Medscape Medical News

Rapid Uptake of Immunotherapy, but Slower in Rural Practices

Overall, immunotherapy was adopted pretty rapidly after it was approved for the treatment of several cancers, but smaller and rural oncologic practices were slower on the uptake. Medscape Medical News

Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer?

Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions. Medscape Medical News

Atezolizumab Fails to Improve Outcomes in Postsurgery Kidney Cancer

"Our results add to an emerging body of literature around the role of adjuvant immunotherapy for renal cell carcinoma. With the longest duration of follow-up to date to our knowledge." MDedge News

New Vaccine Approach Halts Disease After 23 Yrs of Breast Cancer

A combination of immune stimulants and immunotherapy that transforms tumors into cancer vaccine-producing factories has shown remarkable promise in a phase 1/2 trial, although only in 30% of patients. Medscape Medical News

Many Patients at End of Life Still Receiving Cancer Therapy

The use of systemic cancer care at end of life has essentially remained unchanged over the past few years, but the type of therapy has shifted from chemotherapy to immunotherapy. Medscape Medical News

Could Nivolumab Prevent Oral Cancer in High-Risk Patients?

Giving the immunotherapy nivolumab to patients with oral proliferative leukoplakia not only reduces lesions but also may prevent cancer progression, suggests the first study in the preventive setting. Medscape Medical News

Time Management Tips


scattered clouds
20.4 ° C
21.5 °
18.8 °
69 %
40 %
25 °
26 °
23 °
24 °
26 °

Must Read